Influences of dopaminergic treatment on motor cortex in Parkinson disease: a MRI/MRS study.
Identifieur interne : 002537 ( PubMed/Corpus ); précédent : 002536; suivant : 002538Influences of dopaminergic treatment on motor cortex in Parkinson disease: a MRI/MRS study.
Auteurs : Claudio Lucetti ; Paulo Del Dotto ; Gianna Gambaccini ; Roberto Ceravolo ; Chiara Logi ; Caterina Berti ; Giuseppe Rossi ; Maria Cristina Bianchi ; Michela Tosetti ; Luigi Murri ; Ubaldo BonuccelliSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2007.
English descriptors
- KwdEn :
- Adult, Aged, Aspartic Acid (analogs & derivatives), Aspartic Acid (metabolism), Choline (metabolism), Creatinine (metabolism), Dopamine Agonists (therapeutic use), Female, Humans, Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy, Male, Middle Aged, Motor Cortex (drug effects), Motor Cortex (metabolism), Motor Cortex (pathology), Parkinson Disease (drug therapy), Parkinson Disease (metabolism), Parkinson Disease (pathology), Pergolide (therapeutic use), Protons, Treatment Outcome.
- MESH :
- chemical , analogs & derivatives : Aspartic Acid.
- chemical , metabolism : Aspartic Acid, Choline, Creatinine.
- chemical , therapeutic use : Dopamine Agonists, Pergolide.
- drug effects : Motor Cortex.
- drug therapy : Parkinson Disease.
- metabolism : Motor Cortex, Parkinson Disease.
- pathology : Motor Cortex, Parkinson Disease.
- Adult, Aged, Female, Humans, Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy, Male, Middle Aged, Protons, Treatment Outcome.
Abstract
The objective of this study was to investigate neurochemical and metabolic changes in the motor cortex in a group of de novo Parkinson's disease (PD) patients before and after 6 mo treatment with the dopamine agonist pergolide. Proton magnetic resonance spectroscopy (1H-MRS) has been used to study striatal and cortical metabolism in PD and other parkinsonisms. So far, no studies evaluating possible brain metabolic changes in PD patients before and after dopaminergic therapy have been reported. De novo PD patients (11) and controls (11) underwent clinical evaluation (UPDRS-III motor evaluation) and a first single-voxel 1H-MRS of the motor cortex. 1H-MRS studies were performed using the PROBE-SV System implemented on a 1.5 Tesla Scanner (GE Medical System, Milwaukee, WI). Pergolide was administered up to a dose of 1 mg t.i.d. After 6 mo follow-up, all patients were clinically evaluated and a second single-voxel 1H-MRS was performed. Lower values of Cho/Cr and NAA/Cr ratios were observed in the motor cortex of PD patients compared with controls (P < 0.02 and P < 0.01, respectively). After 6 mo therapy with pergolide (1 mg t.i.d), PD patients showed an improvement in motor performances (P < 0.05) and an increase in Cho/Cr ratios in the motor cortex at the second 1H-MRS evaluation (P < 0.05) was reported. In conclusion, cortical NAA/Cr and Cho/Cr ratios may be impaired in de novo PD. Dopaminergic therapy capable of improving motor function may restore the Cho/Cr ratio in the motor cortex.
DOI: 10.1002/mds.21576
PubMed: 17722082
Links to Exploration step
pubmed:17722082Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Influences of dopaminergic treatment on motor cortex in Parkinson disease: a MRI/MRS study.</title><author><name sortKey="Lucetti, Claudio" sort="Lucetti, Claudio" uniqKey="Lucetti C" first="Claudio" last="Lucetti">Claudio Lucetti</name><affiliation><nlm:affiliation>Department of Neuroscience, University of Pisa, Pisa, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Del Dotto, Paulo" sort="Del Dotto, Paulo" uniqKey="Del Dotto P" first="Paulo" last="Del Dotto">Paulo Del Dotto</name></author><author><name sortKey="Gambaccini, Gianna" sort="Gambaccini, Gianna" uniqKey="Gambaccini G" first="Gianna" last="Gambaccini">Gianna Gambaccini</name></author><author><name sortKey="Ceravolo, Roberto" sort="Ceravolo, Roberto" uniqKey="Ceravolo R" first="Roberto" last="Ceravolo">Roberto Ceravolo</name></author><author><name sortKey="Logi, Chiara" sort="Logi, Chiara" uniqKey="Logi C" first="Chiara" last="Logi">Chiara Logi</name></author><author><name sortKey="Berti, Caterina" sort="Berti, Caterina" uniqKey="Berti C" first="Caterina" last="Berti">Caterina Berti</name></author><author><name sortKey="Rossi, Giuseppe" sort="Rossi, Giuseppe" uniqKey="Rossi G" first="Giuseppe" last="Rossi">Giuseppe Rossi</name></author><author><name sortKey="Bianchi, Maria Cristina" sort="Bianchi, Maria Cristina" uniqKey="Bianchi M" first="Maria Cristina" last="Bianchi">Maria Cristina Bianchi</name></author><author><name sortKey="Tosetti, Michela" sort="Tosetti, Michela" uniqKey="Tosetti M" first="Michela" last="Tosetti">Michela Tosetti</name></author><author><name sortKey="Murri, Luigi" sort="Murri, Luigi" uniqKey="Murri L" first="Luigi" last="Murri">Luigi Murri</name></author><author><name sortKey="Bonuccelli, Ubaldo" sort="Bonuccelli, Ubaldo" uniqKey="Bonuccelli U" first="Ubaldo" last="Bonuccelli">Ubaldo Bonuccelli</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="doi">10.1002/mds.21576</idno><idno type="RBID">pubmed:17722082</idno><idno type="pmid">17722082</idno><idno type="wicri:Area/PubMed/Corpus">002537</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Influences of dopaminergic treatment on motor cortex in Parkinson disease: a MRI/MRS study.</title><author><name sortKey="Lucetti, Claudio" sort="Lucetti, Claudio" uniqKey="Lucetti C" first="Claudio" last="Lucetti">Claudio Lucetti</name><affiliation><nlm:affiliation>Department of Neuroscience, University of Pisa, Pisa, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Del Dotto, Paulo" sort="Del Dotto, Paulo" uniqKey="Del Dotto P" first="Paulo" last="Del Dotto">Paulo Del Dotto</name></author><author><name sortKey="Gambaccini, Gianna" sort="Gambaccini, Gianna" uniqKey="Gambaccini G" first="Gianna" last="Gambaccini">Gianna Gambaccini</name></author><author><name sortKey="Ceravolo, Roberto" sort="Ceravolo, Roberto" uniqKey="Ceravolo R" first="Roberto" last="Ceravolo">Roberto Ceravolo</name></author><author><name sortKey="Logi, Chiara" sort="Logi, Chiara" uniqKey="Logi C" first="Chiara" last="Logi">Chiara Logi</name></author><author><name sortKey="Berti, Caterina" sort="Berti, Caterina" uniqKey="Berti C" first="Caterina" last="Berti">Caterina Berti</name></author><author><name sortKey="Rossi, Giuseppe" sort="Rossi, Giuseppe" uniqKey="Rossi G" first="Giuseppe" last="Rossi">Giuseppe Rossi</name></author><author><name sortKey="Bianchi, Maria Cristina" sort="Bianchi, Maria Cristina" uniqKey="Bianchi M" first="Maria Cristina" last="Bianchi">Maria Cristina Bianchi</name></author><author><name sortKey="Tosetti, Michela" sort="Tosetti, Michela" uniqKey="Tosetti M" first="Michela" last="Tosetti">Michela Tosetti</name></author><author><name sortKey="Murri, Luigi" sort="Murri, Luigi" uniqKey="Murri L" first="Luigi" last="Murri">Luigi Murri</name></author><author><name sortKey="Bonuccelli, Ubaldo" sort="Bonuccelli, Ubaldo" uniqKey="Bonuccelli U" first="Ubaldo" last="Bonuccelli">Ubaldo Bonuccelli</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aspartic Acid (analogs & derivatives)</term><term>Aspartic Acid (metabolism)</term><term>Choline (metabolism)</term><term>Creatinine (metabolism)</term><term>Dopamine Agonists (therapeutic use)</term><term>Female</term><term>Humans</term><term>Magnetic Resonance Imaging</term><term>Magnetic Resonance Spectroscopy</term><term>Male</term><term>Middle Aged</term><term>Motor Cortex (drug effects)</term><term>Motor Cortex (metabolism)</term><term>Motor Cortex (pathology)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (metabolism)</term><term>Parkinson Disease (pathology)</term><term>Pergolide (therapeutic use)</term><term>Protons</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Aspartic Acid</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Aspartic Acid</term><term>Choline</term><term>Creatinine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dopamine Agonists</term><term>Pergolide</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Motor Cortex</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Motor Cortex</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Motor Cortex</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Humans</term><term>Magnetic Resonance Imaging</term><term>Magnetic Resonance Spectroscopy</term><term>Male</term><term>Middle Aged</term><term>Protons</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The objective of this study was to investigate neurochemical and metabolic changes in the motor cortex in a group of de novo Parkinson's disease (PD) patients before and after 6 mo treatment with the dopamine agonist pergolide. Proton magnetic resonance spectroscopy (1H-MRS) has been used to study striatal and cortical metabolism in PD and other parkinsonisms. So far, no studies evaluating possible brain metabolic changes in PD patients before and after dopaminergic therapy have been reported. De novo PD patients (11) and controls (11) underwent clinical evaluation (UPDRS-III motor evaluation) and a first single-voxel 1H-MRS of the motor cortex. 1H-MRS studies were performed using the PROBE-SV System implemented on a 1.5 Tesla Scanner (GE Medical System, Milwaukee, WI). Pergolide was administered up to a dose of 1 mg t.i.d. After 6 mo follow-up, all patients were clinically evaluated and a second single-voxel 1H-MRS was performed. Lower values of Cho/Cr and NAA/Cr ratios were observed in the motor cortex of PD patients compared with controls (P < 0.02 and P < 0.01, respectively). After 6 mo therapy with pergolide (1 mg t.i.d), PD patients showed an improvement in motor performances (P < 0.05) and an increase in Cho/Cr ratios in the motor cortex at the second 1H-MRS evaluation (P < 0.05) was reported. In conclusion, cortical NAA/Cr and Cho/Cr ratios may be impaired in de novo PD. Dopaminergic therapy capable of improving motor function may restore the Cho/Cr ratio in the motor cortex.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">17722082</PMID><DateCreated><Year>2007</Year><Month>12</Month><Day>06</Day></DateCreated><DateCompleted><Year>2008</Year><Month>01</Month><Day>31</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>22</Volume><Issue>15</Issue><PubDate><Year>2007</Year><Month>Nov</Month><Day>15</Day></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Influences of dopaminergic treatment on motor cortex in Parkinson disease: a MRI/MRS study.</ArticleTitle><Pagination><MedlinePgn>2170-5</MedlinePgn></Pagination><Abstract><AbstractText>The objective of this study was to investigate neurochemical and metabolic changes in the motor cortex in a group of de novo Parkinson's disease (PD) patients before and after 6 mo treatment with the dopamine agonist pergolide. Proton magnetic resonance spectroscopy (1H-MRS) has been used to study striatal and cortical metabolism in PD and other parkinsonisms. So far, no studies evaluating possible brain metabolic changes in PD patients before and after dopaminergic therapy have been reported. De novo PD patients (11) and controls (11) underwent clinical evaluation (UPDRS-III motor evaluation) and a first single-voxel 1H-MRS of the motor cortex. 1H-MRS studies were performed using the PROBE-SV System implemented on a 1.5 Tesla Scanner (GE Medical System, Milwaukee, WI). Pergolide was administered up to a dose of 1 mg t.i.d. After 6 mo follow-up, all patients were clinically evaluated and a second single-voxel 1H-MRS was performed. Lower values of Cho/Cr and NAA/Cr ratios were observed in the motor cortex of PD patients compared with controls (P < 0.02 and P < 0.01, respectively). After 6 mo therapy with pergolide (1 mg t.i.d), PD patients showed an improvement in motor performances (P < 0.05) and an increase in Cho/Cr ratios in the motor cortex at the second 1H-MRS evaluation (P < 0.05) was reported. In conclusion, cortical NAA/Cr and Cho/Cr ratios may be impaired in de novo PD. Dopaminergic therapy capable of improving motor function may restore the Cho/Cr ratio in the motor cortex.</AbstractText><CopyrightInformation>(c) 2007 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lucetti</LastName><ForeName>Claudio</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del Dotto</LastName><ForeName>Paulo</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Gambaccini</LastName><ForeName>Gianna</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Ceravolo</LastName><ForeName>Roberto</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Logi</LastName><ForeName>Chiara</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Berti</LastName><ForeName>Caterina</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Rossi</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Bianchi</LastName><ForeName>Maria Cristina</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Tosetti</LastName><ForeName>Michela</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Murri</LastName><ForeName>Luigi</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Bonuccelli</LastName><ForeName>Ubaldo</ForeName><Initials>U</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011522">Protons</NameOfSubstance></Chemical><Chemical><RegistryNumber>24MJ822NZ9</RegistryNumber><NameOfSubstance UI="D010479">Pergolide</NameOfSubstance></Chemical><Chemical><RegistryNumber>30KYC7MIAI</RegistryNumber><NameOfSubstance UI="D001224">Aspartic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>997-55-7</RegistryNumber><NameOfSubstance UI="C000179">N-acetylaspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>AYI8EX34EU</RegistryNumber><NameOfSubstance UI="D003404">Creatinine</NameOfSubstance></Chemical><Chemical><RegistryNumber>N91BDP6H0X</RegistryNumber><NameOfSubstance UI="D002794">Choline</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001224">Aspartic Acid</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000031">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002794">Choline</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003404">Creatinine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018491">Dopamine Agonists</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D008279">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D009682">Magnetic Resonance Spectroscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009044">Motor Cortex</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010479">Pergolide</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011522">Protons</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>8</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>2</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>8</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.21576</ArticleId><ArticleId IdType="pubmed">17722082</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002537 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002537 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:17722082
|texte= Influences of dopaminergic treatment on motor cortex in Parkinson disease: a MRI/MRS study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:17722082" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |